Skip to main content

Advertisement

SpringerLink
Log in

Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

It has been hypothesized that polymorphisms expected to result in functional changes in cytokine genes may influence susceptibility to cancer, including malignant melanoma (MM). Here, we have screened 24 potentially functional polymorphisms in five cytokine genes by PCR-SBT and PCR-SSP methods in 122 MM cell lines derived from Caucasian patients. The polymorphic positions studied were: TNFA −1031, −863, −857, −851, −574, −376, −308, −238, +488; TGFB1 −988, −800, −509, +869, +915, +652, +673, +713, +788; IL10 −1082, −819, −592; IL6 −174; IFNG −333, +874. The frequencies of cytokine genotypes of melanoma tumours were compared with those published for healthy Caucasians. It was found that TNFA −238 GA, TGFB1 −509 CT, −800 GG, IFNG +874 AT, IL6 −174 GG, IL10 −1082 GA genotypes were significantly decreased, while TNFA −238 AA, −857 CC, TGFB1 −509 TT, IFNG +874 AA, IL6 −174 CC, IL10 −1082 AA, −819 TT, −592 AA genotypes were significantly increased, in MM. This suggests that genotypes provisionally associated with low expression of pro-inflammatory and immunomodulatory TNF-α, IFN-γ and IL-6 and anti-inflammatory IL-10 and TGF-β1 could be involved in the mechanisms of cancer progression and escape from immunoserveilance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. el-Far M, Fouda M, Yahya R, el-Baz H (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J Physiol Biochem 6:253–258

    Article  Google Scholar 

  2. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS (2005) An interleukin-10 promoter polymorphism may influence tumour development in renal cell carcinoma. J Urol 173:709–712

    Article  PubMed  CAS  Google Scholar 

  3. Howell WM, Calder PC, Grimble RF (2002a) Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 61:447–456

    Article  CAS  Google Scholar 

  4. Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumour necrosis factor in solid tumours: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6:103–107

    PubMed  CAS  Google Scholar 

  5. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68

    Article  PubMed  CAS  Google Scholar 

  6. Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, Oral HB (2005) Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30:41–45

    Article  PubMed  CAS  Google Scholar 

  7. Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH, Tsai FJ (2005) CYP17 and tumour necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol 125:96–99

    Article  PubMed  CAS  Google Scholar 

  8. Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado JC et al (2005) G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334:588–592

    Article  PubMed  CAS  Google Scholar 

  9. Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, Lanas A (2005) No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet 32:299–306

    Article  PubMed  CAS  Google Scholar 

  10. Guo W, Wang N, Li Y, Zhang JH (2005a) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878

    CAS  Google Scholar 

  11. Liu D, O’Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J (2005) Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11:1237–1246

    PubMed  CAS  Google Scholar 

  12. Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, Lee JH, Kim JH, Yoo JY. (2005a) Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225:207–214

    Article  CAS  Google Scholar 

  13. Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L et al (2005) Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine 30:293–302

    Article  PubMed  CAS  Google Scholar 

  14. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005a) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165

    CAS  Google Scholar 

  15. Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C (2005) Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15:53–60

    Article  PubMed  CAS  Google Scholar 

  16. Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25–31

    Article  PubMed  CAS  Google Scholar 

  17. Howell WM, Turner SJ, Theaker JM, Bateman AC (2003) Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30:409–414

    Article  PubMed  CAS  Google Scholar 

  18. Howell WM, Turner SJ, Collins A, Bateman AC, Theaker JM (2002b) Influence of TNFalpha and LTalpha single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur J Immunogenet 29:17–23

    Article  CAS  Google Scholar 

  19. Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Luise Rao M, Maier W, Heun R (2000) Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer’s disease risk in a German population. Neurosci Lett 283:109–112

    Article  PubMed  CAS  Google Scholar 

  20. Constantinidou N (2003) Genotyping for polymorphisms in cytokine genes EFIS, Immunol Lett 87:1–351

    Article  CAS  Google Scholar 

  21. Nancy L, Lucas P, Zachary A, Leffell S (2004) TNF-α, TGF-β, IL-10, IL-6, and INF-γ alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops Part IV. Hum Immunol 65:1413–1419

    Article  CAS  Google Scholar 

  22. Rasmussen SK, Urhammer SA, Jensen J, Hansen T, Borch-Johnsen K, Pedersen O (2000) The −238 and −308 G–>A polymorphisms of the tumour necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 85:1731–1734

    Article  PubMed  CAS  Google Scholar 

  23. Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U, Muller B, Vogelmeier C, von Wichert P (2005b) TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65:93–100

    Article  CAS  Google Scholar 

  24. Spriewald BM, Witzke O, Wassmuth R, Wenzel RR, Arnold ML, Philipp T, Kalden JR (2005) Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s granulomatosis. Ann Rheum Dis 64:457–461

    Article  PubMed  CAS  Google Scholar 

  25. Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E, Martin J (1997) Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 49:74–78

    PubMed  CAS  Google Scholar 

  26. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Aria JM, Inigo P, Sanz S et al (2003) Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:431–435

    Article  PubMed  Google Scholar 

  27. Giedraitis V, He B, Hillert L (1999) Mutation screening of the interferon-gamma gene as a candidate for multiple sclwrosis. Eur J Immunogenet 26:257–259

    Article  PubMed  CAS  Google Scholar 

  28. Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM (2005) TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 191:969–976

    Article  PubMed  CAS  Google Scholar 

  29. Jang WH, Yang Y, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH (2001) The −238 tumour necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 166:41–46

    Article  PubMed  CAS  Google Scholar 

  30. Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, Noh DY, Ahn SH, Hirvonen A, Kang D. (2005b) Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155

    Article  CAS  Google Scholar 

  31. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM (1997) High dose tumour necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 79:1129–1137

    Article  PubMed  CAS  Google Scholar 

  32. Mueller H (1998) Tumour necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 54:1291–1298

    Article  PubMed  CAS  Google Scholar 

  33. Mocellin S, Rossi CR, Pilati P, Nitti D (2004) Tumour necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35–53

    Article  PubMed  CAS  Google Scholar 

  34. Guo W, Wang N, Li Y, Zhang JH (2005b) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878

    CAS  Google Scholar 

  35. Oh BR, Sasaki M, Perinchery G, Ryu S, Park Y, Carroll P, Dahiya R (2000) Frequent genotype changes at −308, and 488 regions of the tumour necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 163:1584–1587

    Article  PubMed  CAS  Google Scholar 

  36. Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumour necrosis factor-alpha gene promoter. Tissue Antigens 52:359–367

    PubMed  CAS  Google Scholar 

  37. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, Maerker-Hermann E, Hoehler T (2000) Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 114:1180–1183

    Article  PubMed  CAS  Google Scholar 

  38. Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005) The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res 24:415–421

    PubMed  CAS  Google Scholar 

  39. Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214

    PubMed  CAS  Google Scholar 

  40. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumour suppression and cancer progression. Nat Genet 29:117–129

    Article  PubMed  CAS  Google Scholar 

  41. Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570

    Article  PubMed  CAS  Google Scholar 

  42. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77:1492–1494

    PubMed  CAS  Google Scholar 

  43. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Lube RN, Chang-Claude J, Mannermaa A, Kataja V et al (2003) A transforming growth factor beta 1 peptide variant increases secretion in vitro and is associated with increased evidence of invasive breast cancer. Cancer Res 63:2610–2615

    PubMed  CAS  Google Scholar 

  44. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin−10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465–469

    Article  PubMed  CAS  Google Scholar 

  45. Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697–703

    Article  PubMed  CAS  Google Scholar 

  46. Kundi MZ, Ahmad I, Anjum M (1997) Evaluation of diarrhoea management of health professionals trained at the Diarrhoea Training Unit of Rawalpindi General Hospital. J Pak Med Assoc 47:3–6

    PubMed  CAS  Google Scholar 

  47. Ishihara K, Hirano T (2002) Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta 1592:281–296

    Article  PubMed  CAS  Google Scholar 

  48. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721–1726

    Article  PubMed  CAS  Google Scholar 

  49. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133–138

    Article  PubMed  CAS  Google Scholar 

  50. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 164:1038–1042

    PubMed  CAS  Google Scholar 

  51. Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumour necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223:113–119

    Article  PubMed  CAS  Google Scholar 

  52. Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–10800

    Article  PubMed  CAS  Google Scholar 

  53. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753–756

    Article  PubMed  CAS  Google Scholar 

  54. Basolo F, Fiore L, Fontanini G, Conaldi PG, Calvo S, Falcone V, Toniolo A (1996) Expression of and response to interleukin 6 (IL6) in human mammary tumours. Cancer Res 56:3118–3122

    PubMed  CAS  Google Scholar 

  55. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A (2000) Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumour cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673–5680

    PubMed  CAS  Google Scholar 

  56. Ozzello L, de Rosa CM, Cantell K, Kauppinen HL, Habif DSr. (1995) Regression of human breast cancer xenografts in response to intralesional treatment with interferons alpha and gamma potentieted by tumour necrosis factor. J. Interferon Cytokine Res 15:839–848

    Article  PubMed  CAS  Google Scholar 

  57. Bubenik J (2005) MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 51:1–2

    CAS  Google Scholar 

Download references

Acknowledgements

This work was funded by the European Commission (contract #QLRI-CT-2001-01235, project ESTDAB) and was partly supported by research grant N-16, Medical University Sofia, Bulgaria.

Author information

Authors and Affiliations

  1. Central Laboratory of Clinical Immunology, University Hospital “Alexandrovska”, 1 Georgy Sofiisky Str., 1431, Sofia, Bulgaria

    Penka N. Nikolova, Snejina M. Mihailova, Milena I. Ivanova, Anastassia P. Myhailova, Daniela N. Baltadjieva, Daniela I. Marinova, Svetlomira S. Ivanova & Elissaveta J. Naumova

  2. University of Tübingen Medical School, Center for Medical Research (ZMF), Tübingen, Germany

    Graham P. Pawelec

Authors
  1. Penka N. Nikolova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graham P. Pawelec
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Snejina M. Mihailova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milena I. Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anastassia P. Myhailova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniela N. Baltadjieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniela I. Marinova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Svetlomira S. Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elissaveta J. Naumova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Penka N. Nikolova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nikolova, P.N., Pawelec, G.P., Mihailova, S.M. et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 56, 371–379 (2007). https://doi.org/10.1007/s00262-006-0193-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-006-0193-z

Keywords

Search

Navigation